"Working at Genentech has offered me the rewarding opportunity to not only contribute to the development of new imaging diagnostics, but also to contribute in the development of treatments for diseases."
I joined Genentech's Biomedical Imaging Group in 2000. My educational background is in biomedical and electrical engineering with a focus on medical imaging and image analysis. Prior to joining Genentech, I had worked in both academia and industry developing imaging methods to study disease and monitor therapy. I chose to come to Genentech because it offers the exciting opportunity to develop novel imaging methods in tandem with the development of novel therapeutics, where imaging can be used not only to assess the efficacy of the compound, but also to provide insight into the mode of action of the drug.
Genentech provides the resources and the collaborative environment needed to tackle such tasks in an efficient and thorough manner. Since joining Genentech, my research efforts have been directed toward the development of micro-computed tomography, MRI, and ultrasound imaging techniques to quantify structural and physiological parameters. Our research efforts focus on developing the appropriate imaging and analysis methodologies that will best answer the biological question we are addressing.
One of the more rewarding experiences I have found at Genentech is being able to mentor post-doctoral researchers as part of Genentech’s Post Doc program. This program allows researchers and their mentors to investigate independent scientific research questions and make use of the tremendous resources that Genentech makes available for research. In addition, working at Genentech provides the post doc student the experience of working in a drug development research environment as they complete their post-doctoral studies and make decisions about future career directions.
Neoplasia. 2013 Nov;15(11):1241-50.
We focus on developing imaging methods and analysis techniques to characterize structural and physiological parameters in a number of disease areas. These efforts span multiple disease areas where MRI, micro-CT or US imaging techniques are chosen based on the modality that is best suited to address the biological question. Major areas of focus include the development of imaging (MRI, U/S, micro-CT) endpoints for fibrosis in a number of fibrotic diseases and MRI endpoints for in-vivo models of neurodegeneration. Fibrotic endpoints include elastography and other more fibrotic-specific endpoints. Neurodegeneration endpoints include brain morphometry techniques (e.g. atlas-based segmentation and voxel-based morphometry) and techniques to quantify the microstructural organization of tissue, such as diffusion tensor imaging. Another area of great interest has been researching novel multispectral MRI methods to identify viable tumor tissue and quantify the pathophysiology of the viable tumor. These methods attempt to address the high degree of structural and physiological heterogeneity seen within solid tumors and provide robust measures to characterize properties of the tumor’s micro-environment (e.g. perfusion, vascularity, tumor oxygenation) and infiltration of immune cells into the viable tumor.
Other areas of research include the development of micro-computed tomography imaging and analysis techniques to quantify bone and cartilage loss in models of rheumatoid arthritis, estimate lung lesion burden tumor burden in genetic oncology models and quantify tissue parameters to describe body composition with whole-body coverage.